FEATURED COMPANIES
- Bayer
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Johnson & Johnson
- Sandoz Inc. (Novartis)
- Viatris Inc.
The global pulmonary arterial hypertension market size is anticipated to reach USD 11.0 billion by 2030. The market is expected to expand at a lucrative CAGR of 5.2% from 2022 to 2030. The key factors driving the market growth include the increasing prevalence of pulmonary arterial hypertension, drug development and technological advancements, product approvals, and initiatives by key companies.
The COVID-19 pandemic had a notable impact on the market. The pandemic created uncertain market conditions and lead to dampened growth. Other impacts of the pandemic include operational challenges, supply chain bottlenecks, challenges in conducting clinical trials, among others. Market players also reported a reduction in new patient starts and new patient prescriptions during 2020.
For instance, the sales of Remodulin, Tyvaso, and Orenitram were affected by the reduction in new patient starts, during the second quarter of 2020. However, the new patient starts gradually recovered to pre-pandemic numbers during the second half of 2020. Market players responded to the COVID-19 pandemic by deploying various initiatives. These included maintaining a strong financial position, maintaining ample supply of products, deploying measures to facilitate uninterrupted distribution to patients, and R&D activities among others. Overall sales of PAH drugs, however, were largely unaffected by the pandemic as market players ensured ample supply during the pandemic.
Supportive product approvals by regulatory agencies such as an extended indication of use, first generics approval, approval of drug delivery devices, etc. are estimated to fuel the market growth in the near future. In March 2021, United Therapeutics’ Tyvaso received FDA clearance for use in patients with pulmonary hypertension associated with interstitial lung disease. In February 2021, the company launched- the Remunity Pump in the U.S.- a new subcutaneous delivery system for its key treprostinil product Remodulin.
This product will be delivered within 1-3 business days.
The COVID-19 pandemic had a notable impact on the market. The pandemic created uncertain market conditions and lead to dampened growth. Other impacts of the pandemic include operational challenges, supply chain bottlenecks, challenges in conducting clinical trials, among others. Market players also reported a reduction in new patient starts and new patient prescriptions during 2020.
For instance, the sales of Remodulin, Tyvaso, and Orenitram were affected by the reduction in new patient starts, during the second quarter of 2020. However, the new patient starts gradually recovered to pre-pandemic numbers during the second half of 2020. Market players responded to the COVID-19 pandemic by deploying various initiatives. These included maintaining a strong financial position, maintaining ample supply of products, deploying measures to facilitate uninterrupted distribution to patients, and R&D activities among others. Overall sales of PAH drugs, however, were largely unaffected by the pandemic as market players ensured ample supply during the pandemic.
Supportive product approvals by regulatory agencies such as an extended indication of use, first generics approval, approval of drug delivery devices, etc. are estimated to fuel the market growth in the near future. In March 2021, United Therapeutics’ Tyvaso received FDA clearance for use in patients with pulmonary hypertension associated with interstitial lung disease. In February 2021, the company launched- the Remunity Pump in the U.S.- a new subcutaneous delivery system for its key treprostinil product Remodulin.
Pulmonary Arterial Hypertension Market Report Highlights
- The market was valued at USD 7.0 billion in 2021 and is expected to expand at a CAGR of 5.2% during the forecast period
- The prostacyclin and prostacyclin analogs segment held the largest share of the market by drug class in 2021. The sales of these drugs are anticipated to grow sharply in the future, primarily due to the growth expected in oral, intravenous, subcutaneous, and inhalational prostacyclin agents
- The branded drugs segment dominated the market in 2021 while the generics segment is anticipated to grow at the fastest rate from 2022 to 2030
- In 2021, the oral segment accounted for the largest revenue share of the market by route of administration owing to the greater availability of PAH formulations as oral products such as tablets, powders, and suspension
- North America dominated the market in 2021 owing to a high adoption rate and supportive infrastructure for the development and distribution of high-quality therapies. Also, the availability of reimbursement on PAH therapies supported market growth
- Asia Pacific is anticipated to witness the fastest CAGR over the forecast period due to its huge population base, rapid economic developments, and improving healthcare infrastructure
This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Pulmonary Arterial Hypertension Market
What is the estimated value of the Global Pulmonary Arterial Hypertension Market?
What is the growth rate of the Global Pulmonary Arterial Hypertension Market?
What is the forecasted size of the Global Pulmonary Arterial Hypertension Market?
Who are the key companies in the Global Pulmonary Arterial Hypertension Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Bayer
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Johnson & Johnson
- Sandoz Inc. (Novartis)
- Viatris Inc.
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Pulmonary Arterial Hypertension Market Variables, Trends & Scope
Chapter 4 COVID - 19 Impact Analysis
Chapter 5 Pulmonary Arterial Hypertension Market: Segment Analysis, By Drug Class, 2017 - 2030 (USD Million)
Chapter 6 Pulmonary Arterial Hypertension Market: Segment Analysis, By Type, 2017 - 2030 (USD Million)
Chapter 7 Pulmonary Arterial Hypertension Market: Segment Analysis, By Route of Administration, 2017 - 2030 (USD Million)
Chapter 8 Pulmonary Arterial Hypertension Market: Regional Market Analysis 2017 - 2030 (USD Million)
Chapter 9 Pulmonary Arterial Hypertension Market - Competitive Analysis
Chapter 10 Pulmonary Arterial Hypertension Market - Company Profiles
List of Tables
List of Figures
Note: Product cover images may vary from those shown
- United Therapeutics Corporation
- Bayer
- Gilead Sciences, Inc.
- Johnson & Johnson
- Viatris Inc.
- GlaxoSmithKline
- Sandoz Inc. (Novartis)
- Lupin Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries, Inc.
- Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
LOADING...